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Abstract
We compared the glycosaminoglycan content of human venous and arterial walls. The most abundant glycosaminoglycan
in human veins is dermatan sulfate whereas chondroitin 4/6-sulfate is preponderant in arteries. The concentrations of
chondroitin 4/6-sulfate and heparan sulfate are V4.8- and V2.5-fold higher in arteries than in veins whereas dermatan
sulfate contents are similar in the two types of blood vessels. Normal and varicose saphenous veins do not differ in their
glycosaminoglycan contents. It is known that certain glycosaminoglycan species from the arterial wall, mainly high-
molecular-weight fractions of dermatan sulfate+chondroitin 4/6-sulfate have greater affinity for plasma LDL. These types of
glycosaminoglycans can be identified on a LDL-affinity column. We now demonstrated that a similar population of
glycosaminoglycan also occurs in veins, although with a lower concentration than in the arteries due to less chondroitin 4/6-
sulfate with affinity for LDL. The concentrations of dermatan sulfate species, which interact with LDL, are similar in arteries
and veins. The presence of these glycosaminoglycans with affinity to plasma LDL in veins raises interesting questions
concerning the role of these molecules in the pathogenesis of atherosclerosis. Possibly, the presence of these
glycosaminoglycans in the vessel wall are not sufficient to cause retention of LDL and consequently endothelial dysfunction,
but may require additional intrinsic factors and/or the hydrodynamic of the blood under the arterial pressure. ß 2002
Elsevier Science B.V. All rights reserved.
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1. Introduction
The basic constituents of the walls of blood vessels
are endothelial cells, smooth muscle cells, and extra-
cellular matrix, including elastic elements, collagen,
and proteoglycans. However, the architecture of the
vessel walls varies with and re£ects distinct function-
al requirements at di¡erent locations. Thus, the rel-
ative amounts of the basic cellular and extracellular
constituents vary along the vascular system owing to
local adaptations to mechanical or metabolic needs.
For example, in order to withstand the pulsatile and
higher blood pressures in arteries, arterial walls are
generally thicker than their venous counterparts.
Veins have a larger overall diameter, a larger lumen
and a thinner wall than the corresponding arteries
[1].
Vascular disease primarily a¡ects arteries, and of
these, the most prevalent and clinically signi¢cant
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problem is atherosclerosis [2]. Veins have a relatively
poor support and are predisposed to abnormal dila-
tion and tortuous veins, known as varicose veins,
produced by prolonged, increased intraluminal pres-
sure and, to a lesser extent, by loss of support of the
vessel walls. Nevertheless, when a segment of vein is
transferred to the arterial system it undergoes phys-
iological and pathological changes, including intimal
thickening and atherosclerosis. This constitutes the
major long-term complication of patients submitted
to coronary artery bypass using grafts of autologous
reversed vein. Many of these patients develop late
recurrence of symptoms because of progression of
atherosclerosis to the vein graft.
In the last years, we [3^6] and several other labo-
ratories [7^10] have studied the glycosaminoglycan
composition of normal and pathological arterial
walls. High concentration of glycosaminoglycan was
shown to occur in this tissue and a speci¢c popula-
tion of high-molecular-weight chondroitin 4/6-sulfa-
te+dermatan sulfate is probably involved in the re-
tention and local deposition of plasma low-density-
lipoprotein into the arterial wall [4,5,11,12]. We now
extend these studies to di¡erent types of normal and
pathological veins. The purpose of the present study
was not only to determine whether the glycosamino-
glycan composition varies from arterial to vein and/
or with speci¢c anatomic location of the venous sys-
tem, but also whether speci¢c populations of vein
glycosaminoglycan have the ability to bind LDL.
The results require a careful interpretation due to
di¡erences of cellular and extracellular components
between arteries and veins [1]. Nevertheless, some
basic aspects related to pathological processes may
be clari¢ed with these results. For example, the ab-
sence of a population of glycosaminoglycan with the
ability to bind LDL could explain the absence of
atherosclerotic lesions in the vein walls. In contrast,
the presence of these glycosaminoglycans in veins
may indicate that additional intrinsic factors of the
arterial bed and its blood-carrying functions in£u-
ence the occurrence of lesions. Our experimental ap-
proach consisted of (1) a detailed characterization of
glycosaminoglycan composition and its concentra-
tion in normal and pathological human veins; (2)
analyses of vein glycosaminoglycan binding to plas-
ma LDL; and (3) further characterization of the gly-
cosaminoglycan samples after LDL binding.
2. Materials and methods
2.1. Materials
Human central veins (jugular, renal, subclavia,
iliaca, cava, porta and pulmonary veins) and thoracic
aortas were obtained from necropsies. Normal sa-
phenous veins were obtained from patients under-
going coronary bypass surgery and varicose leg veins
from patients undergoing vascular surgery. These pa-
tients were aged between 40 and 60 years old, had no
severe diabetes, blood hypertension or extensive
thromboembolic disease. All the samples were pre-
served in acetone until used. In the aorta samples,
after removing the adventitial layer, only the seg-
ments containing the intima+media layers devoid of
macroscopically visible atherosclerotic lesions, were
used for glycosaminoglycan extraction. Samples
were cut into small pieces and subjected to two
changes of 10 volumes of chloroform:methanol
(2:1, v/v) for 24 h each. The ¢nal defatted powder
was obtained by drying this material under vacuum.
Standard chondroitin 4-sulfate, chondroitin 6-sulfate,
dermatan sulfate, dextran sulfate and cyanogen bro-
mide-activated Sepharose 4B were purchased from
Sigma Chemical Co. Chondroitin AC lyase (EC
4.2.2.5) and chondroitin ABC lyase (EC 4.2.2.4)
were from Seikagaku American Inc.
2.2. Isolation of total vessel glycosaminoglycans
The chloroform/methanol-treated venous or arteri-
al powder (100 mg, dry weight) was rehydrated in 3.7
ml of 0.1 M sodium acetate bu¡er (pH 5.0), contain-
ing 5 mM cysteine and 5 mM EDTA at 4‡C for 24 h.
Thereafter, total glycosaminoglycans were isolated
by proteolysis with papain, followed by subsequent
cetylpyridinium and ethanol precipitations, as de-
scribed previously [5,6]. The ¢nal pellet was dried
under vacuum and dissolved in 1.0 ml distilled water.
Total glycosaminoglycan contents in the samples
were estimated by determination of hexuronic acid
concentration of the ¢nal solutions [13]. Under these
conditions, papain digestion completely solubilized
all vessel samples, and controls using known
amounts of glycosaminoglycans showed that recov-
ery from the subsequent cetylpyridinium and ethanol
precipitation was greater than 90%.
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2.3. Fractionation and characterization of the
vessel glycosaminoglycans
Fractionation of the glycosaminoglycans was per-
formed by anion exchange chromatography on a
Mono Q-FPLC column. The eluted fractions were
assayed by the metachromasy produced by sulfated
glycosaminoglycans with 1,9-dimethyl methylene
blue [14] and by hexuronic acid content using the
carbazole reaction [13]. Fractions were pooled, dia-
lyzed against distilled water, lyophilized and then
dissolved in distilled water.
Sulfated glycosaminoglycans separated on the
Mono Q-FPLC were identi¢ed by agarose gel elec-
trophoresis. In this experiment glycosaminoglycans
(V10 Wg) were applied to a 0.5% agarose gel in
0.05 M 1,3-diaminopropane/acetate bu¡er (pH 9.0)
before and after subsequent treatments of the sam-
ples with chondroitin AC lyase, chondroitin ABC
lyase and nitrous acid. After electrophoresis (120 V
for 1 h), the glycosaminoglycans in the gel were ¢xed
with 0.1% N-cetyl-N,N,N-trimethylammonium bro-
mide in water, stained with 0.1% toluidine blue in
acetic acid/ethanol/water (0.1:5:5, v/v), and washed
for about 30 min in acetic acid/ethanol/water
(0.1:5:5, v/v). The relative proportions of chondro-
itin 4/6-sulfate and dermatan sulfate were estimated
by densitometry using a model GS-690 imaging den-
sitometer (Bio-Rad Laboratories). Three replicate
densitometric pro¢les were obtained for each sample.
In terms of peak height and position, the replicates
did not vary more than 5% from the pro¢les shown
in the ¢gures.
The molecular weights of the glycosaminoglycan
chains were estimated by polyacrylamide gel electro-
phoresis. Glycosaminoglycan samples (V10 Wg) were
applied to a 6% 1-mm-thick polyacrylamide gel slab
in 0.02 M sodium barbital bu¡er (pH 8.6). After
electrophoresis (100 V for 30 min), the gel was
stained with 0.1% toluidine blue in 1% acetic acid,
and washed for about 4 h in 1% acetic acid. The
molecular weight markers were the same as those
used previously [15]. In a previous study [4], we esti-
mated the molecular weight of aortic glycosamino-
glycans by gel ¢ltration and polyacrylamide gel elec-
trophoresis. The two methods have nearly identical
accuracy. But we used the latter method in this study
because it requires a smaller amount of sample.
2.4. Isolation of LDL from plasma
LDL (d = 1.019^1.063 g/ml) was puri¢ed by the
method of Havel et al. [16], using human plasma
obtained from healthy donors. After sequential ultra-
centrifugations in KBr, the LDL preparation was
dialyzed at 4‡C against 0.9% NaCl containing
0.01% EDTA and 0.01% NaN3. Purity of LDL in
this preparation was assessed by agarose gel electro-
phoresis in barbital bu¡er. The LDL migrated as a
single band.
2.5. Interaction between LDL and glycosaminoglycans
Experiments on the interaction between LDL and
vessel glycosaminoglycan were performed essentially
as described elsewhere, using LDL-a⁄nity chroma-
tography [3^6].
The LDL-a⁄nity column was constructed by cou-
pling the ligand to CNBr-activated Sepharose 4B ac-
cording to the protocol supplied with the product
(Pharmacia). The e⁄cacy of the procedure used for
binding LDL to Sepharose 4B was assessed by mea-
suring the cholesterol content of the resin. A control
column was prepared in the same way but without
the lipoprotein. To avoid natural variations in LDL
obtained from di¡erent individuals, LDL obtained
from a single healthy donor was used for all a⁄nity
columns. However, three replicate analyses of the
same glycosaminoglycan mixture on LDL-a⁄nity
columns prepared with LDL from di¡erent healthy
donors replicates did not vary more than 10% in
terms of the amounts of glycosaminoglycans retained
by the columns and of chondroitin 4/6-sulfate:der-
matan sulfate ratios in the retained fractions.
About 100 Wg (as hexuronic acid) of glycosamino-
glycan in 1 ml of bu¡er was applied to LDL^Sephar-
ose column (0.7U8.0 cm) pre-equilibrated with 5 mM
Tris^HCl bu¡er (pH 7.4) containing 10 mM CaCl2.
After the column was washed with 20 ml of the same
bu¡er, the retained material was eluted using a linear
NaCl gradient. Eluted fractions were analyzed by
their metachromatic property [14] and by their hex-
uronic acid content [13]. A control column was made
by identical treatment of the resin but omitting the
lipoprotein. Aortic glycosaminoglycans were not sig-
ni¢cantly retained on this column (5% of the applied
sample). See also Tovar et al. [17].
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3. Results
3.1. Glycosaminoglycan content of human veins
The total glycosaminoglycan content, as deter-
mined by the hexuronic acid assay, is signi¢cantly
higher in the saphenous than in the several central
veins (Table 1). In contrast, no di¡erence was
observed between normal saphenous and varicose
leg veins. Nevertheless, all types of veins included
in this study had a signi¢cant lower content of
glycosaminoglycan than thoracic aorta (Table 1)
or other types of arteries that we had studied
previously [5], such as iliac and pulmonary ar-
teries.
Chromatography on Mono Q-FPLC separates the
glycosaminoglycans into three peaks, namely, the hy-
aluronic acid, heparan sulfate and dermatan sulfate
+chondroitin 4/6-sulfate fractions, as exempli¢ed in
Fig. 1A for normal saphenous vein. No variations
were observed in the NaCl concentrations necessary
for elution of the three peaks in di¡erent types of
veins, but the relative amounts in each peak (based
on hexuronic acid content) varied with the type of
veins. The identities of the three fractions of glycos-
aminoglycans were established as follows: hyaluronic
Fig. 1. Fractionation of glycosaminoglycans from normal saphenous vein by ion exchange chromatography (A) and characterization
of the puri¢ed fractions by agarose gel electrophoresis (B,C). (A) A solution (1 ml) containing V200 Wg (as hexuronic acid) of glyco-
saminoglycans extracted from normal saphenous vein was applied to a Mono Q-FPLC column (HR 5/5) equilibrated with 20 mM
Tris^HCl bu¡er. The column was developed by a linear gradient of 0.15^1.5 M NaCl in the same bu¡er using a £ow rate of 0.45 ml/
min. Fractions of 0.5 ml were collected and assayed for metachromasia (a), hexuronic acid (b), and NaCl concentration (----). Frac-
tions were pooled as indicated (horizontal bars) and precipitated with three volumes of ethanol. Recovered materials were identi¢ed
as hyaluronic acid (HA), heparan sulfate (HS), and dermatan sulfate+chondroitin 4/6-sulfate (DS/CS), as described in the text. (B,C)
Samples (V10 Wg) of heparan sulfate and dermatan sulfate+chondroitin 4/6-sulfate, puri¢ed on the Mono Q-FPLC, were applied to a
0.5% agarose gel in 0.05 M 1,3-diaminopropane/acetate bu¡er (pH 9.0). After electrophoresis, the glycosaminoglycans in the gel were
¢xed with 0.1% N-cetyl-N,N,N-trimethylammonium bromide and stained with toluidine blue (see Section 2). Standard glycosaminogly-
cans used were chondroitin 4-sulfate from whale cartilage, dermatan sulfate from pig skin and heparan sulfate from human aorta.
The proportions of chondroitin 4/6-sulfate and dermatan sulfate were quanti¢ed by densitometry, and a typical pro¢le is shown in
(C). The dermatan sulfate peak is crosshatched. Panels show typical chromatographic and electrophoretic pro¢les in terms of intensity
and position of the bands, as observed among glycosaminoglycan samples from 14 saphenous veins. See [5,6] for additional informa-
tion about the methodology used in the experiments.
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acid is not detected by agarose gel electrophoresis
but forms unsaturated non-sulfated disaccharide
(vGlcUA-GlcNAc) by chondroitin AC lyase diges-
tion (not shown). The heparan sulfate fraction mi-
grated on agarose gel electrophoresis as the standard
of heparan sulfate (Fig. 1B), resisted chondroitin AC
or ABC lyase digestion, but was degraded by deam-
ination cleavage with nitrous acid (not shown). The
third fraction from Mono Q-FPLC contained a mix-
ture of dermatan sulfate and chondroitin 4/6-sulfate,
as demonstrated by agarose gel electrophoresis (Fig.
1B). Incubation of this fraction with chondroitin AC
lyase only degraded the glycosaminoglycan with an
electrophoretic migration similar to that of standard
chondroitin 4/6-sulfate, and generated a peak that
co-migrates with the standard of dermatan sulfate.
Finally, treatment with chondroitin ABC lyase de-
graded the glycosaminoglycans producing an electro-
phoretic migration similar of standard of chondroitin
4/6-sulfate and dermatan sulfate (not shown). The
relative proportions of these two glycosaminoglycans
were quanti¢ed by densitometry of the agarose gel
electrophoresis, and a typical pro¢le for glycosami-
noglycans extracted from normal saphenous vein is
shown in Fig. 1C.
Dermatan sulfate+chondroitin 4/6-sulfate from
veins and arteries were eluted from Mono Q-FPLC
with similar NaCl concentrations (compare data of
Fig. 1A with those of reference [6]. Thus, these gly-
cosaminoglycans from the two types of vessels had
similar charge density. In addition, dermatan sulfate
+chondroitin 4/6-sulfate from veins and arteries did
not yield signi¢cant amounts (s 5%) of non-sulfated
or disulfated disaccharides after digestion with chon-
droitin ABC lyase.
From the data on the relative proportions of the
three fractions of glycosaminoglycans estimated on
Mono Q-FPLC (Fig. 1A), the relative proportion
Table 2
Relative proportions of dermatan sulfate and chondroitin 4/6-sulfate in fractions from LDL-a⁄nity chromatography
Vessel Relative proportion (%)
Retained on the LDL-column Non-retained on the LDL-column
Normal saphenous vein 39 61
Varicose saphenous vein 38 62
Thoracic aorta 39 61
The dermatan sulfate+chondroitin 4/6-sulfate fractions from ion exchange chromatography were applied to LDL-a⁄nity columns and
the subjected to elution with an increasing linear gradient of NaCl. Obtained fractions were pooled as retained and non-retained frac-
tions (see Fig. 3) and the proportions of these two fractions were determined based on the hexuronic acid content.
Table 1
Total glycosaminoglycan content (as hexuronic acid) in di¡erent types of human vessels
Vessel Hexuronic acid (Wg/mg of dry, defatted tissue;
Mean þ S.E.M.)
n
Jugular vein 1.43 þ 0.68 4
Subclavia vein 1.86 1
Cava vein 1.12 þ 0.02 2
Pulmonary vein 1.49 þ 0.44 2
Renal vein 1.98 þ 0.06 2
Portal vein 1.03 þ 0.13 2
Il|¤aca vein 1.06 þ 0.25 2
All central veins 1.39 þ 0.48* 15
Saphenous vein ^ normal 2.18 þ 0.56*a 14
Saphenous vein ^ varicose 2.55 þ 0.65a 5
Thoracic aortab 4.42 þ 0.87 22
*P6 0.002.
aNot signi¢cant.
bSee also Tovar et al. [6].
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of chondroitin 4/6-sulfate and dermatan sulfate (Fig.
1C) and total glycosaminoglycan content (Table 1),
the concentrations of the four species in human veins
and arteries could be estimated (Fig. 2). The amount
of hyaluronic acid was quite variable and we could
not establish signi¢cant di¡erences among vein sam-
ples (data not shown). Clearly, the most abundant
glycosaminoglycan in human veins is dermatan sul-
fate whereas chondroitin 4/6-sulfate is preponderant
in thoracic aortas (Fig. 2). In fact, chondroitin 4/6-
sulfate is V4^8-fold more concentrated in human
arteries than in veins (Fig. 2, CS), whereas the di¡er-
ences in the concentration of dermatan sulfate be-
tween the two types of vessels are not very pro-
Fig. 3. LDL-a⁄nity chromatography of venous and arterial
dermatan sulfate+chondroitin 4/6-sulfate. About 100 Wg (as hex-
uronic acid) of dermatan sulfate+chondroitin 4/6-sulfate from
normal and varicose saphenous vein and from thoracic aorta,
puri¢ed by Mono Q-FPLC (see Fig. 1), was applied to an
LDL^Sepharose column (0.7U8.0 cm) and eluted using a linear
gradient (see Section 2). Eluted fractions were assayed for meta-
chromasia (a), hexuronic acid (b) and NaCl concentration
(öö). Fractions corresponding to retained (R) and non-re-
tained (non-R) glycosaminoglycans were pooled as indicated
(horizontal bars) and precipitated with three volumes of abso-
lute ethanol. The precipitated glycosaminoglycans were dis-
solved in distilled water and used for the experiments shown in
Table 3 and Fig. 4.
Fig. 2. Glycosaminoglycan contents in thoracic aorta and in
normal and varicose veins. Contents of chondroitin 4/6-sulfate
(CS), dermatan sulfate (DS) and heparan sulfate (HS) are given
in Wg of hexuronic acid per mg of dry, defatted tissue. Hexur-
onic acid content in total glycosaminoglycan extract was mea-
sured using carbazole reaction (see Table 1). In combination
with the data from anion exchange chromatography (Fig. 1A)
and agarose gel electrophoresis (Fig. 1C), these data permit esti-
mation of the concentrations of the individual glycosaminogly-
can species in the several types of vessels. *P6 0.002; **not sig-
ni¢cant.
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nounced (Fig. 2, DS). Again, the contents of the
three species of sulfated glycosaminoglycans are sig-
ni¢cantly higher in the saphenous than in the central
veins whereas no di¡erence was observed between
normal and varicose leg veins.
3.2. Interaction between plasma LDL and
glycosaminoglycans extracted from the
human veins
A direct measurement of the interaction between
the glycosaminoglycans extracted from vein wall and
plasma LDL was undertaken using a⁄nity chroma-
tography. A column was prepared by coupling hu-
man LDL to Sepharose 4B, and to this column the
puri¢ed dermatan sulfate+chondroitin 4/6-sulfate
fractions were applied (Fig. 3). Vessel heparan sulfate
is virtually not retained. To obtain a quantitative
index of the interaction with LDL, we compared
the amount of total dermatan sulfate+chondroitin
4/6-sulfate retained on the a⁄nity column with the
total amount applied. The proportion of retained
glycosaminoglycan is similar for aortic aorta and sa-
phenous vein, including pathological varicose vein
(Table 2), and all glycosaminoglycans were eluted
from the column with the same concentration of
NaCl (Fig. 3).
The proportions of dermatan sulfate and chon-
droitin 4/6-sulfate in the fractions retained and
non-retained on the LDL-a⁄nity column were deter-
mined by agarose gel electrophoresis (not shown but
the same methodology exempli¢ed in Fig. 1B,C) and
the quantitative results are shown in Table 3. Der-
matan sulfate from arterial wall is constituted mostly
of glycosaminoglycan chains with a comparatively
high a⁄nity for LDL, as a signi¢cant proportion
of this compound was retained by the LDL-column.
The relative content of chondroitin 4/6-sulfate, on
the other hand, decreased in inverse relation, which
indicates that chains with a comparatively low a⁄n-
ity for LDL are the major constituents of this glycos-
aminoglycan. In contrast, for the glycosaminoglycans
from the venous wall the proportion of dermatan
sulfate and chondroitin 4/6-sulfate did not vary dra-
matically between the fraction with and without af-
¢nity for LDL.
Combining the data of the proportions of glycos-
aminoglycan retained and non-retained on the
LDL-a⁄nity column (Table 2), the relative propor-
tions of dermatan sulfate and chondroitin 4/6-sul-
Table 4
Content of dermatan sulfate and chondroitin 4/6-sulfate with and without a⁄nity for plasma LDL in human vessels
Vessel Retained on the LDL-column Non-retained on the LDL-column
DS CS Total DS CS Total
Normal saphenous vein 0.35 0.18 0.53 0.43 0.38 0.81
Varicose saphenous vein 0.28 0.26 0.54 0.42 0.47 0.89
Thoracic aorta 0.38 0.85 1.23 0.29 1.64 1.93
The contents of dermatan sulfate (DS) and chondroitin 4/6-sulfate (CS) with and without a⁄nity for LDL (as Wg of hexuronic acid/
mg of dry, defatted tissue) were determined combining the data of the proportions of the two glycosaminoglycan retained and not-re-
tained on the LDL-column (Fig. 3, Table 2) with those of relative proportions (Table 3) and total content of the glycosaminoglycans
in the vessels (Fig. 2).
Table 3
Relative proportions of dermatan sulfate and chondroitin 4/6-sulfate in fractions from LDL-a⁄nity chromatography
Vessel Retained on the LDL-column Non-retained on the LDL-column
DS CS Ratio DS/CS DS CS Ratio DS/CS
Normal saphenous vein 66 34 1.94 53 47 1.13
Varicose saphenous vein 52 48 1.08 47 53 0.89
Thoracic aorta 31 69 0.45 15 85 0.17
The relative amounts of dermatan sulfate (DS) and chondroitin 4/6-sulfate (CS) retained and non-retained on an LDL-a⁄nity column
were determined by agarose gel electrophoresis, as exempli¢ed in Fig. 1B,C.
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fate in fractions with and without a⁄nity for LDL
(Table 3) with those for total glycosaminoglycan
contents (Fig. 2) allowed us to estimate the concen-
trations of dermatan sulfate and chondroitin 4/6-sul-
fate with and without a⁄nity for plasma LDL in
human aorta and in the normal and varicose saphe-
nous veins (Table 4). The total content of dermatan
sulfate+chondroitin 4/6-sulfate retained on the
LDL-a⁄nity column is V2.2-fold higher in artery
than in vein. However, the content of dermatan sul-
fate that interact with LDL was not markedly di¡er-
ent in the two types of vessels, always in the range
of 0.29^0.43 Wg hexuronic acid/mg of dry, defatted
tissue. In contrast, the contents of chondroitin 4/6-
sulfate, both with and without a⁄nity for LDL,
increase markedly from the venous to the arterial
wall (approximately 4-fold more concentrated in ar-
tery than in vein).
Finally, polyacrylamide gel electrophoresis of the
fractions from the LDL-a⁄nity column (Fig. 4)
showed that dermatan sulfate+chondroitin 4/6-sul-
fate that interacts with LDL always had a higher
apparent molecular weight than the fractions not re-
tained by the column. Thus, fractions retained on the
LDL-column had a lower electrophoretic mobility on
polyacrylamide gel than the non-retained fractions
(compare lanes named R and NR in Fig. 4), denot-
ing higher molecular weight of the glycan chains that
interact with LDL. Nevertheless, the molecular
weights of the retained glycans were somewhat vari-
able among the venous and arterial fractions.
4. Discussion
4.1. Venous and arterial walls di¡er in their
glycosaminoglycan content
Studies about the glycosaminoglycan content of
normal and pathological arteries are abundant [3^
9,18,19], but similar analysis with veins is scarce.
The preponderance of dermatan sulfate in normal
saphenous veins was suggested in two previous
works [20,21]. We now performed a systematic com-
parison between the glycosaminoglycan contents of
venous and arterial walls. Glycosaminoglycans were
extracted from the tissue by proteolysis and partially
puri¢ed by precipitation with a cationic detergent.
After ion exchange chromatography, total glycos-
aminoglycan extracts yield three peaks, identi¢ed as
hyaluronic acid, heparan sulfate, and a mixture of
dermatan sulfate+chondroitin 4/6-sulfate (Fig. 1).
The most abundant glycosaminoglycan in human
veins is dermatan sulfate (Fig. 2B), whereas chon-
droitin 4/6-sulfate is preponderant in arteries (Fig.
2A, see also [5,6]). Chondroitin 4/6-sulfate and hep-
aran sulfate are V4.8- and V2.5-fold, respectively,
more concentrated in arteries than in veins whereas
dermatan sulfate contents are similar in the two
types of vessels. Normal and varicose saphenous
veins did not di¡er in their glycosaminoglycan con-
tent. But, surprisingly, saphenous veins had a higher
content of glycosaminoglycan than central veins (Ta-
ble 1) due to an overall increase in the three types of
sulfated glycosaminoglycans (Fig. 2). Some di¡eren-
ces between the content of glycosaminoglycans in
venous wall reported by us and other authors [20^
22] may be due to the methodologies used for extrac-
tion and characterization of these compounds and/or
variation in the anatomic sections of the veins used
in these studies.
The architecture of arterial and venous walls dif-
fers mostly due to variations in the relative amounts
of basic cellular and extracellular constituents. For
Fig. 4. Molecular weight of the dermatan sulfate+chondroitin
4/6-sulfate eluted from a LDL-a⁄nity column. Samples (10 Wg)
of retained (R) and non-retained (NR) fractions from saphe-
nous vein and thoracic aorta were run on 6% polyacrylamide
gels in sodium barbital bu¡er (pH 8.6) and stained with 0.1%
toluidine blue in 1% acetic acid. Molecular weight markers used
were chondroitin 6-sulfate from shark cartilage (St4; average
molecular weight 60 kDa), chondroitin 4-sulfate from whale
cartilage (St3; average molecular weight 30 kDa), dermatan sul-
fate from pig skin (St2; average molecular weight 20 kDa), and
dextran sulfate (St1; average molecular weight 8 kDa).
BBADIS 62085 26-4-02
G.C. Leta et al. / Biochimica et Biophysica Acta 1586 (2002) 243^253250
example, the thicker media in the arterial rather than
in venous wall may explain the dramatic di¡erence in
their heparan sulfate content, which supposed to be
mainly produced by the endothelial cells of the inti-
ma layer [23,24]. But the arterial wall has also a
higher chondroitin sulfate content, possibly a prod-
uct from the smooth muscle cells [25]. In this case we
would expect that smooth muscle cells from the two
types of vessels synthesize di¡erent proportions of
chondroitin 4/6-sulfate and dermatan sulfate. The
drastic di¡erences we reported for the glycosamino-
glycan contents of arteries and veins may also re£ect
variations in the proportions of cell/extracellular ma-
trix in these two vessels. Obviously all these possibil-
ities require further investigation, especially concern-
ing the question whether similar cells from the two
vessels synthesize di¡erent types and/or proportions
of glycosaminoglycans.
Similar proteoglycans occur in veins and arteries,
although in di¡erent proportions. Thus, versican, de-
corin and biglycan have been reported in saphenous
veins [22]. Dermatan sulfate may be attached to dif-
ferent proteoglycans from the vein wall. It remains to
be clari¢ed which population of dermatan sulfate-
rich proteoglycan is particularly enriched in the ve-
nous wall.
4.2. Content of dermatan sulfate with a⁄nity for
plasma LDL does not vary from artery to vein
A direct measurement of the interaction between
venous glycosaminoglycans and plasma LDL was
undertaken using a⁄nity chromatography. This
methodology was previously used by us [3^6] and
other groups [11,26] to study the interaction between
plasma LDL and the glycosaminoglycans extracted
from aorta or produced by cells derived from the
tissue. For this interaction with plasma LDL glycos-
aminoglycan chains do not require the attachment
to the protein core [6]. In addition, blocking of
some amino groups on the apo-B lipoprotein during
the preparation of the a⁄nity column is not detri-
mental to use this method for detecting formation of
LDL^glycosaminoglycan complexes [17]. With the
use of this methodology we observed that the total
content of dermatan sulfate+chondroitin 4/6-sulfate
retained on the LDL-a⁄nity column is V2.2-fold
higher in artery than in vein. However, this di¡erence
is mostly attributed to a lower content in the venous
wall of chondroitin 4/6-sulfate with a⁄nity for LDL,
which is V3.86-fold more concentrated in arterial
than in venous walls. In contrast, the content of der-
matan sulfate that interacted with plasma LDL was
not markedly di¡erent in the two types of vessels
(Table 4).
Iverius [27] observed a preferential binding of der-
matan sulfate to LDL and a role of this glycosami-
noglycan in the development of the atherosclerotic
lesions was postulated [27,28]. These results con-
trasted with other studies in which chondroitin 4/6-
sulfate was shown to interact with plasma LDL
[29,30]. These apparently contradictory reports were
reconciled by the observation that high-molecular-
weight chains of both glycosaminoglycans can inter-
act with LDL [3,4]. The fact that aortic dermatan
sulfate constitutes most of the glycosaminoglycans
with a high a⁄nity for LDL is ascribed to their com-
paratively longer glycan chains compared with chon-
droitin 4/6-sulfate [3,4]. Unlike proteins, glycosami-
noglycans occur naturally as polydisperse polymers,
that is, their degree of polymerization, and hence
their molecular weights, vary considerably. This pa-
rameter a¡ects binding of dermatan sulfate and
chondroitin 4/6-sulfate chains to LDL [5,6]. The
fact that aortic dermatan sulfate constitutes most
of the glycosaminoglycans with a high a⁄nity for
LDL due to their comparatively longer glycan chains
compared with chondroitin 4/6-sulfate [5,6].
A similar conclusion was reached in investigations
on synthesis of glycosaminoglycans by arterial
smooth muscle cells under di¡erent experimental
conditions. In these cells, the shift from the resting
to proliferating condition has been implicated in
atherogenesis. This shift is accompanied by an in-
crease in the synthesis of proteoglycans with higher
a⁄nity for plasma LDL, due essentially to an in-
crease in size of their chondroitin 4/6-sulfate chains
[11]. Among the complex array of mediators taking
part in atherogenesis, growth factors are capable of
inducing phenotypic changes in arterial smooth
muscle cells and also of increasing the synthesis of
proteoglycans [31]. More important, the proteogly-
cans synthesized under these conditions have longer
glycosaminoglycan chains [12].
We now observed that the fraction of venous der-
matan sulfate+chondroitin 4/6-sulfate retained on
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LDL-a⁄nity column always had a higher molecular
weight than the non-retained fraction (Fig. 4). This
¢nding extend to vein the observation about the pos-
itive correlation between the molecular size of der-
matan sulfate+chondroitin 4/6-sulfate chains and in-
teraction with LDL, although the molecular weight
of the retained glycans are somewhat variable be-
tween vein and artery.
4.3. What is the signi¢cance of the glycosaminoglycan
species in venous wall with high a⁄nity for
plasma LDL?
It is well established that proteoglycans and their
glycosaminoglycan chains contribute to pathogenesis
of atherosclerosis by retaining and modifying LDL
that insudates into the arterial wall. The nature of
the glycosaminoglycan^LDL interaction has been ex-
tensively studied, and it is known that certain glycos-
aminoglycan species, including particular popula-
tions of a given species, have greater a⁄nity for
LDL. We now demonstrated that a similar popula-
tion of glycosaminoglycan also occurs in the venous
wall although at a lower concentration than in artery
due to less chondroitin 4/6-sulfate chains with a⁄nity
for plasma LDL.
Venous and arterial glycosaminoglycans were
eluted from the LDL-column at NaCl concentrations
below physiological level. Very high concentrations
of glycosaminoglycans are found on the vessel walls.
Thus, if plasma LDL binds vessel glycosaminoglycan
avidly at normal salt concentration in vivo, we would
expect a rapid accumulation of the lipoprotein on the
vessel walls. Perhaps, this means that glycosamino-
glycan chains require low-salt concentrations for
binding LDL in vitro. At physiological salt concen-
trations, in vivo binding of glycosaminoglycan to
plasma LDL probably requires additional factors,
such as fusion of LDL particles [32] or certain lipases
known to enhance the association of lipoproteins
with smooth muscle cells and extracellular matrix
[33,34].
Previously we demonstrated that it is unlikely that
the increased risk for developing atherosclerotic le-
sions in older arteries results from altered glycosami-
noglycan composition [6]. Possibly increasing athero-
sclerosis with age simply re£ects the longer time
available for lipid accumulation to occur, and not
changes in glycosaminoglycan composition in older
arteries that favor an increased binding of LDL with
age.
The presence of similar glycosaminoglycan popu-
lations with a⁄nity for plasma LDL in venous wall
rise interesting questions due to the absence of athe-
rosclerotic lesions in veins. Possibly, the presence of
these glycosaminoglycan populations in the venous
wall is not su⁄cient to cause endothelial dysfunc-
tion but requires additional intrinsic factors and/or
the hydrodynamic of the blood under the arterial
pressure. In fact, when segments of saphenous veins
are transferred to the arterial system during coro-
nary artery bypass they develop atherosclerosis
[19,20].
Our results rise not only intrigued basic questions
concerning the role of glycosaminoglycans in the
pathogenesis of atherosclerosis but also have some
practical aspects. Thus, vein segments (mostly from
saphenous vein) are extensively used for coronary
artery bypass. A long-term complication of these sur-
geries is the progression of atherosclerosis to the vein
graft. Other types of vessels have been tested as an
alternative to the saphenous vein. For example, the
internal mammary artery graft has shown less long-
term complications than saphenous vein graft [19]. A
possible biochemical explanation for this observation
is di¡erence in the content of glycosaminoglycan
with high a⁄nity for LDL in the two types of vessels.
Interestingly, the relative proportions of the glycos-
aminoglycans do not appear to modify dramatically
after the transfer of saphenous vein segment to the
arterial system [21]. Possibly, the methodology de-
scribed in our study may constitute an appropriated
way to search for more appropriated vessels for cor-
onary bypass, less susceptible to long-term progres-
sion of atherosclerosis.
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